Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2006 1
2007 1
2008 1
2010 1
2011 3
2012 4
2013 2
2014 2
2015 3
2016 2
2018 2
2019 1
2020 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. van Rhee F, et al. Among authors: schey s. Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. Blood. 2018. PMID: 30181172 Free PMC article.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. van Rhee F, et al. Among authors: schey s. Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334. Blood Adv. 2020. PMID: 33284946 Free PMC article.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Miguel JS, et al. Among authors: schey s. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3. Lancet Oncol. 2013. PMID: 24007748 Clinical Trial.
The management of Castleman disease.
Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, Ramasamy K; British Society for Haematology (BSH) Committee. Lomas OC, et al. Among authors: schey s. Br J Haematol. 2021 Nov;195(3):328-337. doi: 10.1111/bjh.17688. Epub 2021 Aug 2. Br J Haematol. 2021. PMID: 34340261 No abstract available.
Pomalidomide therapy for myeloma.
Schey S, Ramasamy K. Schey S, et al. Expert Opin Investig Drugs. 2011 May;20(5):691-700. doi: 10.1517/13543784.2011.567265. Epub 2011 Mar 18. Expert Opin Investig Drugs. 2011. PMID: 21413906 Review.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Chan WY, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh J, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Clifton-Hadley L, Rabin N, Owen RG, Popat R, Yong KL; PADIMAC investigators. Chan WY, et al. Among authors: schey s. Br J Haematol. 2022 Feb;196(4):e33-e37. doi: 10.1111/bjh.17903. Epub 2021 Oct 11. Br J Haematol. 2022. PMID: 34636043 Clinical Trial. No abstract available.
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Ramasamy K, Iqbal G, Brouwer R, Stalker V, Akhtar S, Varghese S, Lindsay J, Schey S, Drayson M, Dunn J. Ramasamy K, et al. Among authors: schey s. Blood Cancer J. 2022 Nov 29;12(11):162. doi: 10.1038/s41408-022-00758-7. Blood Cancer J. 2022. PMID: 36446771 Free PMC article. Clinical Trial. No abstract available.
Rituximab and thalidomide combination therapy for Castleman disease.
Ramasamy K, Gandhi S, Tenant-Flowers M, Ceesay M, Corderoy S, Marcus R, Schey S. Ramasamy K, et al. Among authors: schey s. Br J Haematol. 2012 Aug;158(3):421-3. doi: 10.1111/j.1365-2141.2012.09157.x. Epub 2012 May 14. Br J Haematol. 2012. PMID: 22583139 Free article. No abstract available.
27 results